Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022
[ad_1] STOCKHOLM, Dec. 21, 2022 /PRNewswire/ — Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced today that CEO Renée Aguiar-Lucander has net purchased 50,000 shares through Calliditas’ warrant program 2019/2022. Following the new subscription for shares, her shareholding in the company will amount to 643,000 common shares. The majority of the members […]